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Condensation 
The rate of trisomy 21 among fetuses with an AVSD in the second trimester is 
high even in those that undergo first trimester combined screening. 
 
Short version of title 
AVSD and trisomy 21. 
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ABSTRACT 
Objective: Atrioventricular septal defect is associated with a high risk of a 
chromosomal abnormality, particularly trisomy 21. The aim of this study is to 
assess the rate of trisomy 21 in fetuses diagnosed with an atrioventricular 
septal defect and to examine the influence of prior screening on the rate of 
trisomy 21.  
Methods: Electronic ultrasound database was searched to identify fetuses 
diagnoses with an atrioventricular septal defect from 2002 to 2014. Rate of 
trisomy 21 and other aneuploidies was calculated among fetuses with normal 
situs. The prevalence of trisomy 21 and other aneuploidies was assessed in 
women with low and high first trimester risk for trisomy 21, using a cut-off value 
of 1:150 and 1:250. 
Results: A total 110 fetuses with a diagnosis of atrioventricular septal defect 
were identified. Among the 98 fetuses with normal situs, the prevalence of 
trisomy 21 was 46% (95%CI: 36-56%). Using a 1:150 threshold, the rate of 
trisomy 21 within the low-risk group was 41% (95%CI: 27-57%) while in the 
high-risk group it was 70% (95% CI: 52-83%), significantly higher than in the 
low risk group (p= 0.028). Similar results were obtained when the 1:250 
threshold was applied (66% versus 41%, p= 0.055). 
Conclusions: The rate of trisomy 21 among fetuses identified with an 
atrioventricular septal defect in the second trimester is high even in those that 
undergo first trimester combined screening. Some fetuses with a high-risk 
screening result show a normal karyotype. Therefore, an offer of an invasive 
 4 
procedure to check fetal karyotyping is indicated. Knowledge of these rates may 
be helpful for parents in the decision making process.  
 
Key words: atrioventricular septal defect, AVSD, chromosomal abnormalities, 
trisomy 21, first trimester risk, combined risk. 
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INTRODUCTION 
Atrioventricular septal defect (AVSD) is a common cardiac abnormality with an 
estimated incidence ranging from 0.24/1000 to 0.31/1000 live births.1 Its 
anatomical hallmark involves the presence of a common atrioventricular 
junction, but a wide spectrum of abnormalities exists. In a complete AVSD there 
are variable size atrial and ventricular septal defects, and a single valve orifice. 
In a partial AVSD there are two atrioventricular valve orifices, and this is most 
commonly associated with a defect in the primum (inferior) part of the atrial 
septum, an ostium primum defect.2 
Fetal AVSD has known associations with aneuploidies and situs abnormalities. 
The association is strongest for trisomy 21, which is present in about 40% of 
fetuses with an AVSD.3,4,5 It is also known that in fetuses with trisomy 21, AVSD 
is a common malformation.6 Because of this, the finding of an AVSD during a 
genetic sonogram represents an indication to offer fetal invasive prenatal 
testing for karyotype.7  
First trimester screening using combined screening for trisomy 21 has led to 
large increases in antenatal detection.8,9 As a consequence of this increased 
detection rate, one would expect a reduction in the prevalence of trisomy 21 in 
the second trimester overall, but also in the subgroup of fetuses with an AVSD –
There is some evidence of this from published literature. 10 We undertook this 
study with two aims: to assess the rate of trisomy 21 in a population of fetuses 
diagnosed with an AVSD; and to examine the influence of prior screening on 
the rate of trisomy 21.  
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MATERIALS AND METHODS 
The Fetal Medicine Unit of St. George’s Hospital, London, UK, is a tertiary 
referral centre for the diagnosis and management of all fetal conditions. 
Pregnant women where a screening scan reveals a concern are referred to our 
unit both from our own hospital (approx. 5,000 births per year) and the South-
West Thames region (five maternity units, with approx. 20,000 births per year).  
We undertook a search of our electronic database (Viewpoint) to identify all 
those fetuses diagnosed with an AVSD from 2002 to 2014. Maternal details, the 
indication for referral, gestational age at the time of diagnosis of the AVSD, 
ultrasound findings, presence of any associated abnormalities, information 
regarding fetal karyotype, nuchal translucency (NT) measurement and the 
estimated risk for trisomy 21 at the first trimester screening, and pregnancy 
outcome were extracted. Details of fetal karyotype were cross-checked with a 
separate cytogenetic database maintained in the Department of Genetics.  
The first trimester risk was obtained by a combination of maternal age, fetal NT 
thickness and maternal serum free beta-human Chorionic Gonadotrophin (hCG) 
and pregnancy associated plasma protein-A (PAPP-A) at 11+0–13+6 weeks.11 
When data regarding maternal serum data were not available, the first trimester 
risk was obtained by combination of maternal age and fetal NT.12 Finally, when 
neither were available (women declining screening), the risk was calculated 
based on maternal age alone for the purposes of this study.13 
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Following referral, fetuses underwent complete ultrasound evaluation of fetal 
anatomy in addition to fetal echocardiography. Invasive testing was offered to 
all women, and the results were recorded. Fetal karyotype was obtained after 
birth where parents declined prenatal invasive testing. 
Institutional Review Board approval was given for the collection of pregnancy 
outcome data as part of follow-up of fetal medicine unit patients. 
Statistics 
Descriptive data are presented as median and inter-quartile ranges (IQR). 
Proportions are presented as percentage and 95% CI. Statistical analysis was 
performed using the SPSS V20.0. The chi-squared test was used to evaluate 
inter-group differences. P-values of <0.05 have been considered statistically 
significant. 
RESULTS 
Overall 110 fetuses with a diagnosis of AVSD were identified. The median 
gestational age at diagnosis was 21 weeks (IQR: 17.6-22.4); median maternal 
age was 33 years (IQR: 27-38); median maternal BMI was 25.7 (IQR: 22.9- 
29.8); median NT value in the first trimester was 2.7 mm (IQR: 1.9 – 4.5); 
median first trimester risk for trisomy 21 was 1:184 (IQR: 1:918 – 1: 16). 
Information regarding fetal karyotype was available for 100 fetuses (91%). In 11 
cases the parents declined invasive testing during pregnancy and the 
investigation for karyotyping was performed post-natally. Details regarding 
karyotype, indication for referral and pregnancy outcome of the 110 fetuses with 
an AVSD are given in Table 1. The rate of trisomy 21 among the 110 cases was 
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41% (95% CI: 32-50%). There were twelve cases where the AVSD was found in 
the presence of abnormal situs (Supplementary Table 1); in this group there 
was one case of trisomy 18 but none with trisomy 21. These fetuses were 
excluded from subsequent analysis. 
Among the remaining 98 fetuses with AVSD and normal situs, the prevalence of 
trisomy 21 was 45 of 98 (46%, 95% CI: 36-56%), the karyotype was normal in 
35 (36%, 95% CI: 27-46%) and not available in 9 (9%, 95% CI: 5-17%) cases. 
In these 98 fetuses with AVSD and normal situs we identified 69 with an 
isolated AVSD, and 29 with an AVSD associated with other abnormalities (listed 
in Table 2). In fetuses with isolated AVSDs, the most common karyotype 
abnormality was trisomy 21, found in 37 of 69 fetuses (54%, 95% CI: 42-65%). 
The karyotype was normal in 22 cases (32%, 95% CI: 22-44%), and unavailable 
in 5 (7%, 95% CI: 3-16%). When the AVSD was non-isolated, the prevalence of 
trisomy 21 was lower, with 8 of 29 fetuses showing trisomy 21 (28%, 95% CI: 
15-46%), 13 with normal karyotype (45%, 95% CI: 28-63%) and 4 (14%, 95% 
CI: 5-31%) in which it was unavailable. Additional information is available in 
Table 3. 
Within the isolated AVSD group (n=69), we further investigated the prevalence 
of trisomy 21 among the cases with low and high first trimester risk for trisomy 
21. When the estimation of the first trimester risk was lower than 1:150, 
pregnancies were included in the low risk group (median risk = 1:814; IQR= 
1:386 – 1:1681). Among these pregnancies the rate of trisomy 21 was 41% 
(95% CI: 27-57%), while the karyotype was normal in 49% (95% CI: 34-64%) of 
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cases. If the first trimester risk was equal or higher than 1:150, women were 
included in the high-risk group (median risk = 1:10; IQR= 1:2 – 1:45). Among 
them the prevalence of trisomy 21 was 70% (95% CI: 52-83%), and karyotype 
was normal in 10% (95% CI: 4-26%) of cases. The prevalence of trisomy 21 in 
the high risk group was significantly higher than in the low risk group (70% 
versus 41%, p= 0.028) (Table 4). In many European countries a different cut off 
of 1:250 is used to classify the pregnancies in high and low risk. Using a cut off 
of 1:250 the results did not vary. The risk in the low-risk group remained high, 
but lower than in the high-risk group (66% versus 41%, p= 0.055) (Table 4). 
COMMENT 
The findings of the study show that the overall rate of trisomy 21 among fetuses 
with an AVSD and normal situs is 45.9% (95% CI: 36.4-55.6%). There was 
some evidence of an effect of first trimester screening on the prevalence of 
trisomy 21: the rate of trisomy 21 was significantly higher in women that had 
previously had a positive first trimester combined test (70%) than in those who 
were screen –negative (41%). Nevertheless this prevalence of 41% means that 
karyotipic examination should still be offered. The findings also show that four 
out of the 33 fetuses (12%) with AVSD from the high risk group had normal 
karyotype.    
The rate of trisomy 21 among fetuses with a diagnosis of AVSD has been 
reported to be around 40%.3,4,6 These studies were performed in the 1990s, 
before the introduction of the first trimester screening in the clinical practice. 
Since 2001, the introduction of the first trimester screening for trisomy 21, has 
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led to a 70% increase in the antenatal detection of trisomy 21.8,9 Following this 
improvement, we expected to find a lower prevalence of trisomy 21 among 
fetuses diagnosed with an AVSD in the 2nd trimester, and a higher proportion of 
fetuses with an AVSD and normal karyotype, as a consequence of detection 
and subsequent termination of at least some of the affected pregnancies. 
Contrary to expectations, we found that the rate of trisomy 21 in fetuses with 
AVSD has remained stable since 1990s, being 45% in our series. A possible 
explanation to this is available in a UK epidemiological study investigating 
trends in diagnosis and live births of fetuses affected by Down’s syndrome. This 
study8 shows that the annual number of trisomy 21 live births has remained 
steady since 1990s, as the number of pregnancies that are detected and where 
the parents opt for pregnancy termination is balanced by the age-related 
increase. This may partly explain why the rate of trisomy 21 in fetuses with an 
AVSD in the second trimester is stable at around 40% in our study.  We 
speculate that the number of pregnancies detected (and where parents choose 
termination) is balanced by those resulting from increased maternal age, 
leading to a similar number of fetuses with trisomy 21 and an AVSD reaching 
the second trimester.  
A recent study10 reported on trisomy 21 from 1992 – 2012.  They reported that 
complex congenital heart defects were less common in the latter years in 
infants diagnosed with Down syndrome. This phenotypic shift could be a result 
of selective termination of fetuses with Down syndrome.  In addition to this, a 
proportion of women with an increased first trimester risk opted against prenatal 
diagnosis; and of those undergoing prenatal diagnosis of trisomy 21, 
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approximately one in ten will opt to continue the pregnancy.8 This is supported 
by our observation that the diagnosis of aneuploidy was already known at the 
time of fetal echocardiography in 15% of the fetuses and was the reason for the 
referral to the fetal cardiologist. 
Another aim of this study was to assess the role of the first trimester risk in the 
prediction of trisomy 21 after detection of an AVSD in the 2nd trimester.15 We 
wanted to explore if, in the presence of an AVSD and a low first trimester risk, 
the chance of trisomy 21 remains low. Indeed, the risk of trisomy 21 after 
detection of an AVSD is an important factor in parental decision making. We 
found that although the rate of trisomy 21 is higher in the group of women with a 
high first trimester risk (>1:150) and an AVSD (70%, 95%CI: 52-83%), the 
absolute rate remains high in the group with a low first trimester risk (41%, 95% 
CI: 27-57%), a difference which does not vary significantly when the chosen 
threshold is 1:250 (66% versus 41%). In a previous study3 conducted before the 
introduction of screening by NT and combined testing, the risk of trisomy 21 in 
fetuses with an AVSD was assessed by taking into account the age-related 
maternal risk and the relative risk was found to be 107. The authors concluded 
that with such a high relative risk, even in the presence of a very low first 
trimester risk (e.g. 1:1000), the final risk calculated in the second trimester 
would still be high (e.g. 1:10).  In our study, we examined the rate of trisomy 21 
in fetuses with an AVSD in two separate groups with low and high risk in the 
first trimester. Although we found a significant difference, with a rate of 70% in 
the high-risk group compared with a rate of 41% in the low-risk group, we 
believe that in both groups the rates are still high and that an offer of 
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amniocentesis in the presence of an AVSD is still indicated, irrespective of the 
risk in the first trimester. Indeed, given that the final management is guided by 
parental choice, the rate of trisomy 21 in the low and high-risk group is still a 
useful information in the decision making process. 
One limitation of our study is that fetal karyotype was unknown in about the 9% 
of cases and clearly, this may have led to a underestimation of the rate of 
chromosomal abnormalities. One more limitation is the missing maternal serum-
free beta-hCG and PAPP-A levels in 12 pregnancies and missing NT 
measurements in 18 pregnancies. It may be also argued that the present study 
tends to overestimate the real incidence of AVSD due to a selection bias. Some 
fetuses had been referred because of increased NT, which in itself, is 
associated with heart defects regardless of karyotype.16,17 However only 17% of 
our series had this indication (increased NT), and exclusion of these fetuses 
from our analysis did not change our results. Some other fetuses were referred 
for a known trisomy 21. This may have led to an increase in the rate of trisomy 
21 among the group with a high first trimester risk, as most of them (11 out of 
16) belonged to that group. Another limitation is related to an intervention bias: 
this was likely to occur in the high-risk group as many trisomy 21 cases could 
have been terminated. These predominantly increased NT cases would have 
had a high incidence of cardiac anomalies – hence the prevalence of trisomy 21 
in the high-risk group in this study might be lower than would naturally be 
observed. We cannot be sure that all the AVSDs diagnosed after birth were 
detected antenatally. Such defects might have been less likely to be affected 
with trisomy 21. Hence the study prevalence of trisomy 21 in the low-risk group 
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may be higher than would naturally be observed. Alternatively, it has been 
reported that fetuses with AVSD associated with trisomy 21 have less distorted 
cardiac anatomy. 18 Therefore, some fetuses with isolated AVSD with trisomy 
21 may not have been detected antenatally. However, the database was 
matched with the regional genetic database of chromosomal abnormalities, and 
prenatally undiagnosed cases of trisomy 21 with AVSD were not found. 
Observational bias may affect the low-risk group. A proportion of women knew 
that the fetus was affected with trisomy 21. The data from this study is of no use 
to these prospective parents. However, the data are still useful to couple faced 
with a diagnosis of AVSD in the second trimester. It will help them in making an 
informed choice. Access to cell-free DNA testing technology has provided 
additional alternatives to couples with a fetus suspected to have Down 
syndrome. However, this technology was not available during the study period.  
Despite the introduction of the first trimester combined screening the rate of 
trisomy 21 among fetuses diagnosed with an AVSD in the second trimester is 
still high. Given the high rates both in the low and high-risk group, the option of 
karyotyping should be given to the parents. At the same time, a small proportion 
of fetuses with AVSD and high risk on antenatal screening have a normal 
karyotype. Therefore, karyotyping should be carried out before concluding that 
the fetus with AVSD and a high risk screening result is affected with Down 
syndrome. The knowledge of these rates may be helpful for parents in the 
decision making process.  
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Table 1 
Details regarding fetal karyotype, indication for referral to fetal cardiologist and pregnancy outcome among 116 fetuses diagnosed with 
an atrioventricular septal defect in the second trimester. NT: nuchal translucency; u/k: unknown; IUD: intra-uterine death; NND: 
neonatal death. 
 
Karyotype n % (95%CI)   Indication n % (95%CI)   Outcome n % (95%CI) 
Normal 49 42.2 (33.6-51.3)   Suspected cardiac defect 62 53.4 (44.4-62.3)   Livebirth 62 53.4 (44.4-62.3) 
Trisomy 21 46 39.7 (31.2-48,8)   Increased NT, u/k karyotype 18 15.5 (10-23.2)   Termination 36 31.0 (23.3-39.9) 
Trisomy 18 7 6.0 (3.0-11.9)   Trisomy 21 16 13.8 (8.7-21.2)   IUD 12 10.3 (6-17.2) 
Trisomy 13 1 0.9 (0.2-4.7)   Increased NT, normal karyotype 9 7.8 (4.1-14.1)   NND 5 4.3 (1.9-9.7) 
45X 1 0.9 (0.2-4.7)   Multiple abnormalities 4 3.4 (1.3-8.5)   Ongoing 1 0.9 (0.2-4.7) 
XXY 1 0.9 (0.2-4.7)   Heart difficult to image 5 4.3 (1.9-9.7)         
Not available 11 9.5 (5.4-16.2)   Family history 2 1.7 (0.5-6.1)         
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Table 2 
Associated abnormalities. Data are given as absolute numbers. In the presence of any of the listed soft markers the AVSD was 
considered isolated if only one soft marker was identified, while in the presence of two of more soft markers the AVSD was defined 
non-isolated. 
*: fetuses found with any of the marked cardiac abnormalities were excluded from analysis as such fetuses are well known to have a 
very low rate of chromosomal abnormalities (Berg 2003, Langford 2005). 
 
Associated abnormalities n Cardiac abnormalities n 
Brachycepahly 5 *Left isomerism 6 
Persistent increased NT/cystic hygroma 4 *Right isomerism 6 
Hemivertebra 2 Tetralogy of Fallot 8 
Strawberry shaped head 1 Pulmonary atresia 5 
Micrognathia 1 Pleural effusion 5 
Cleft lip 1 Bilateral SVCs 4 
    Heart block 4 
Posterior fossa cyst 2 Pericardial effusion 2 
Partial agenesis of cerebellar vermis 1 Double outlet right ventricle 1 
Small cerebellum 1 Double inlet right ventricle 1 
    
Congenital diaphragmatic hernia 1 Soft markers n 
Thoracic dysplasia 1 Ventriculomegaly 6 
    Choroid plexus cysts 5 
Absent radius 1 Hydronephrosis 4 
Bilateral talipes 1 2 vessels cord 4 
Rocker bottom feet 1 Short long bones 2 
      
Oesofageal atresia 2     
Exomphalos 1     
Enlarged kidneys 1     
 20 
Duodenal atresia 1     
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Table 3 Details regarding fetal karyotype, indication for referral to fetal cardiologist and pregnancy outcome among 103 fetuses with 
an atrioventricular septal defect (AVSD) diagnosed in the second trimester and normal situs, among 72 fetuses with normal situs and 
an isolated AVSD, and among 31 fetuses with normal situs and non-isolated AVSD. NT: nuchal translucency; u/k: unknown; IUD: 
intra-uterine death; NND: neonatal death. 
AVSD with NORMAL SITUS (n: 103)  
Karyotype n % (95%CI)   Indication n % (95%CI)   Outcome n % (95%CI) 
Normal 
38 36.9 (28.2-46.5) 
  Suspected cardiac defect 
53 51.5 (41.9-60.9) 
  Livebirth 
56 
54.4 (44.8-
63.7) 
Trisomy 21 
46 44.7 (35.4-54.3) 
  Increased NT, u/k karyotype 
17 16.5 (10.6-24.9) 
  Termination 
32 
31.1 (22.9-
40.5) 
Trisomy 18 6 5.8 (2.7-12.1)   Trisomy 21 16 15.5 (9.8-23.8)   IUD 11 10.7 (6.1-18.1) 
Trisomy 13 1 1.0 (0.2-5.3)   Increased NT, normal karyotype 7 6.8 (3.3-13.4)   NND 3 2.9 (1-8.2) 
45X 1 1.0 (0.2-5.3)   Multiple abnormalities 4 3.9 (1.5-9.6)   Ongoing 1 1.0 (0.2-5.3) 
XXY 1 1.0 (0.2-5.3)   Heart difficult to image 4 3.9 (1.5-9.6)         
Not available 10 9.7 (5.4-17)   Family history 2 1.9 (0.5-6.8)         
                      
ISOLATED AVSD (n: 72) 
Karyotype n % (95%CI)   Indication n % (95%CI)   Outcome n % (95%CI) 
Normal 23 31.9 (22.3-43.4)   Suspected cardiac defect 39 54.2 (42.7-65.2)   Livebirth 44 61.1 (49.6-
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71.5) 
Trisomy 21 38 52.8 (41.4-63.9)   Increased NT, u/k karyotype 11 15.3 (8.8-25.3)   Termination 18 25 (16.4-36.1) 
Trisomy 18 3 4.2 (1.4-11.5)   Trisomy 21 15 20.8 (13.1-31.6)   IUD 8 11.1 (5.7-20.4) 
Trisomy 13 0 0   Increased NT, normal karyotype 1 1.4 (0.2-7.5)   NND 1 1.4 (0.2-7.5) 
45X 1 1.4 (0.2-7.5)   Multiple abnormalities 0 0   Ongoing 1 1.4 (0.2-7.5) 
XXY 1 1.4 (0.2-7.5)   Heart difficult to image 4 5.6 (2.2-13.4)         
Not available 6 8.3 (3.9-17)   Family history 2 2.8 (0.8-9.6)         
                      
NON-ISOLATED AVSD (n: 31) 
Karyotype n % (95%CI)   Indication n % (95%CI)   Outcome n % (95%CI) 
Normal 
15 48.4 (32-65.2) 
  Suspected cardiac defect 
14 45.2 (29.2-62.2) 
  Livebirth 
12 
38.7 (23.7-
56.2) 
Trisomy 21 
8 25.8 (13.7-43.2) 
  Increased NT, u/k karyotype 
6 19.4 (9.2-36.3) 
  Termination 
14 
45.2 (29.2-
62.2) 
Trisomy 18 3 9.7 (3.3-24.9)   Trisomy 21 1 3.2 (0.6-16.2)   IUD 3 9.7 (3.3-24.9) 
Trisomy 13 1 3.2 (0.6-16.2)   Increased NT, normal karyotype 6 19.4 (9.2-36.3)   NND 2 6.5 (1.8-20.7) 
45X 0 0   Multiple abnormalities 4 12.9 (5.1-28.9)   Ongoing 0 0 
XXY 0 0   Heart difficult to image 0 0         
Not available 4 12.9 (5.1-28.8)   Family history 0 0         
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Table 4 
Prevalence of chromosomal abnormalities among women a diagnosis of isolated atrioventricular septal defect (AVSD) in the second 
trimester, according to the first trimester risk for trisomy 21. *Low-risk group: women with isolated AVSD, normal situs, first trimester 
risk <1:150. °High risk group: women with isolated AVSD, normal situs, first trimester risk >1:150.  
 
  *Low-risk group (n: 39) °High risk group (n: 33)   
  n % (95%CI) n % (95%CI) p 
Karyotype 39 % 33     
Normal 19 48.7  (33.9-63.8) 4 12.1 (4.8-27.3) p=0.001 
Trisomy 21 16 41.0 (27.1-56.6) 22 66.7 (49.6-80.2) p=0.036 
Trisomy 18 2 5.1 (1.4-16.9) 1 3.0 (0.5-15.3)   
Trisomy 13 0   0     
45X 0   1 3.0 (0.5-15.3)   
XXY 1 2.6 (0.5-13.2) 0     
Not available 1 2.6 (0.5-13.2) 5 15.2 (6.7-30.9) p=0.087 
 
 
 
 
